Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Bao, Bin ^a   Ali, Shadan ^a   Ahmad, Aamir ^a   Azmi, Asfar S ^a   Li, Yiwei ^a   Banerjee, Sanjeev ^a   Kong, Dejuan ^a   Sethi, Seema ^a   Aboukameel, Amro ^a   Padhye, Subhash B ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISTRA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; KI 67 ANTIGEN; LEUKEMIA INHIBITORY FACTOR; MICRORNA 21; MICRORNA 210; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL RENEWAL; CELL SURVIVAL; CLONOGENESIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UPREGULATION; VASCULAR ENDOTHELIUM;

ANOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CURCUMIN; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICRORNAS; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84871261049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050165     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
2. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, et al. (2010) Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 170(9): 791-802.
3. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, et al. (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19): 1407-1427.
4. Jubb AM, Buffa FM, Harris AL, (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14 (1-2):: 18-29.
5. Moulder JE, Rockwell S, (1987) Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5 (4):: 313-341.
6. Sarkar FH, Li Y, Wang Z, Kong D, (2009) Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 64 (5):: 489-500.
7. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, et al. (2012) The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta.
8. DeSano JT, Xu L, (2009) MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J 11 (4):: 682-692.
9. Perera RJ, Ray A, (2007) MicroRNAs in the search for understanding human diseases. BioDrugs 21 (2):: 97-104.
10. Cao P, Deng Z, Wan M, Huang W, Cramer SD, et al. (2010) MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9: 108.
11. Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, et al. (2007) Regulation of microRNA expression: the hypoxic component. Cell Cycle 6 (12):: 1426-1431.
12. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M, (2008) A microRNA component of the hypoxic response. Cell Death Differ 15 (4):: 667-671.
13. Pocock R, (2011) Invited review: decoding the microRNA response to hypoxia. Pflugers Arch 461 (3):: 307-315.
14. Pang Y, Young CY, Yuan H, (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42 (6):: 363-369.
15. Quero L, Dubois L, Lieuwes NG, Hennequin C, Lambin P, (2011) miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol.
16. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, et al. (2010) Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 10 (5):: 372-387.
17. Bao B, Ali S, Banerjee S, Wang Z, Logna F, et al. (2012) Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression. Cancer Res 72 (1):: 335-345.
18. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, et al. (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70 (9):: 3606-3617.
19. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, et al. (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6 (3):: e17850.
20. Kong D, Banerjee S, Huang W, Li Y, Wang Z, et al. (2008) Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68 (6):: 1927-1934.
21. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27 (8):: 1712-1721.
22. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, et al. (2012) Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells. Cancer Prev Res (Phila).
23. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. (2006) MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 1: e116.
24. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27 (5):: 1859-1867.
25. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, et al. (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9 (5):: 617-628.
26. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71 (13):: 4640-4652.
27. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M, (2008) MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12 (12):: 2171-2176.
28. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, et al. (2009) MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8 (5):: 1067-1074.
29. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, et al. (2011) MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 6 (4):: e19139.
30. Nie Y, Han BM, Liu XB, Yang JJ, Wang F, et al. (2011) Identification of MicroRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 7 (6):: 762-768.
31. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, et al. (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126 (1):: 73-80.
32. Devlin C, Greco S, Martelli F, Ivan M, (2011) miR-210: More than a silent player in hypoxia. IUBMB Life 63 (2):: 94-100.
33. Hu S, Huang M, Li Z, Jia F, Ghosh Z, et al. (2010) MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122 (11 Suppl):: S124-S131.
34. Huang X, Le QT, Giaccia AJ, (2010) MiR-210-micromanager of the hypoxia pathway. Trends Mol Med 16 (5):: 230-237.
35. Kondo S, Ueno H, Hashimoto J, Morizane C, Koizumi F, et al. (2012) Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. BMC Cancer 12 (1):: 268.
36. Scheller J, Rose-John S, (2006) Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 195 (4):: 173-183.
37. Fisman EZ, Tenenbaum A, (2010) The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol 9: 62.
38. Yi H, Cho HJ, Cho SM, Jo K, Park JA, et al. (2012) Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells. Korean J Physiol Pharmacol 16 (1):: 11-16.
39. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, et al. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61 (24):: 8851-8858.
40. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE, (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3 (8):: e3077.
41. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24 (16):: 1731-1745.
42. Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, et al. (2010) Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 9 (1):: 430-443.
43. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV, (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65 (111):: 1631-1652.
44. Narayan S, (2004) Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol 35 (3):: 301-307.
45. Shehzad A, Wahid F, Lee YS, (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343 (9):: 489-499.
46. Mukherjee PK, Maity N, Nema NK, Sarkar BK, (2011) Bioactive compounds from natural resources against skin aging. Phytomedicine 19 (1):: 64-73.
47. Sarkar FH, Li Y, (2009) Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35 (7):: 597-607.
48. Sarkar FH, Li Y, Wang Z, Padhye S, (2010) Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 16 (16):: 1801-1812.
49. Wang Z, Desmoulin S, Banerjee S, Kong D, Li Y, et al. (2008) Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci 83 (7-8):: 293-300.
50. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, et al. (2011) Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem 112 (1):: 78-88.